# Luxembourg Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Luxembourg HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Luxembourg (LUX) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $132.8M - Products: 30 - Buyer markets: 28 - Average CAGR: +13.5% - Global sector size: $680.2B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $310.3B | $121.5M | $116.5B | +14.4% | 22 | +0.0% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $147.6B | $136.6K | $58.3B | -10.2% | 12 | +0.0% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $24.8B | $2.0M | $18.3B | +27.6% | 9 | +0.0% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $381.3K | $15.9B | -4.1% | 8 | +0.0% | | HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $11.4B | $7.0K | $14.8B | +10.4% | 2 | +0.0% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $13.4B | $55.5K | $12.3B | +11.8% | 5 | +0.0% | | HS 300220 - Vaccines: for human medicine | $11.5B | $63.6K | $11.6B | +21.0% | 3 | +0.0% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $19.7B | $1.6M | $10.3B | +139.0% | 3 | +0.0% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $15.9B | $10.0K | $9.6B | -4.2% | 4 | +0.0% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $182.3K | $8.5B | +18.7% | 3 | +0.0% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.2B | $2.3M | $8.0B | +27.1% | 4 | +0.0% | | HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $24.8K | $6.7B | +8.4% | 1 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $2.5M | $6.3B | +2.1% | 3 | +0.0% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $7.8B | $981.0K | $6.2B | +9.8% | 2 | +0.0% | | HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $2.6K | $4.8B | +23.0% | 1 | +0.0% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $3.6B | $7.2K | $4.7B | -40.1% | 2 | +0.0% | | HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $3.1B | $3.6K | $4.4B | +67.7% | 2 | +0.0% | | HS 330300 - Perfumes and toilet waters | $6.6B | $855.0K | $4.1B | +26.8% | 2 | +0.0% | | HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $37.6K | $3.8B | -1.7% | 2 | +0.0% | | HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $3.5B | $14.5K | $3.2B | +40.2% | 1 | +0.0% | | HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $1.6B | $7.4 | $3.1B | +5.9% | 1 | +0.0% | | HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $679.1 | $1.7B | -0.6% | 1 | +0.0% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $310.2 | $1.4B | +5.9% | 1 | +0.0% | | HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $104.9K | $1.4B | +45.4% | 1 | +0.0% | | HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $2.8B | $40.6 | $1.3B | -34.7% | 1 | +0.0% | | HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $14.1 | $1.2B | -30.2% | 1 | +0.0% | | HS 281820 - Aluminium oxide: other than artificial corundum | $2.3B | $645.1 | $1.1B | +54.4% | 1 | +0.0% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $382.2 | $1.1B | -28.4% | 1 | +0.0% | | HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $55.4 | $1.1B | -12.4% | 1 | +0.0% | | HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $7.0K | $1.0B | +42.9% | 1 | +0.0% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $70.4B calculated opportunity across 12 products. - Germany (DEU): $41.7B calculated opportunity across 13 products. - Switzerland, Liechtenstein (CHE): $33.3B calculated opportunity across 3 products. - Belgium (BEL): $31.7B calculated opportunity across 7 products. - Italy (ITA): $25.1B calculated opportunity across 5 products. - China (CHN): $21.3B calculated opportunity across 7 products. - Netherlands (NLD): $20.7B calculated opportunity across 6 products. - Slovenia (SVN): $12.9B calculated opportunity across 2 products. - United Kingdom (GBR): $10.7B calculated opportunity across 5 products. - France (FRA): $10.5B calculated opportunity across 5 products. - Canada (CAN): $9.0B calculated opportunity across 5 products. - Spain (ESP): $8.9B calculated opportunity across 4 products. ## Growth stars - HS 300212: +139.0% average CAGR, $10.3B calculated opportunity. - HS 284190: +67.7% average CAGR, $4.4B calculated opportunity. - HS 281820: +54.4% average CAGR, $1.1B calculated opportunity. - HS 340220: +45.4% average CAGR, $1.4B calculated opportunity. - HS 300290: +42.9% average CAGR, $1.0B calculated opportunity. - HS 293359: +40.2% average CAGR, $3.2B calculated opportunity. - HS 382499: +27.6% average CAGR, $18.3B calculated opportunity. - HS 330499: +27.1% average CAGR, $8.0B calculated opportunity. - HS 330300: +26.8% average CAGR, $4.1B calculated opportunity. - HS 293379: +23.0% average CAGR, $4.8B calculated opportunity. ## Diversification opportunities - HS 300490: 22 buyer markets, $116.5B calculated opportunity. - HS 300215: 12 buyer markets, $58.3B calculated opportunity. - HS 382499: 9 buyer markets, $18.3B calculated opportunity. - HS 300439: 8 buyer markets, $15.9B calculated opportunity. - HS 382600: 5 buyer markets, $12.3B calculated opportunity. - HS 300214: 4 buyer markets, $9.6B calculated opportunity. - HS 330499: 4 buyer markets, $8.0B calculated opportunity. - HS 300220: 3 buyer markets, $11.6B calculated opportunity. - HS 300212: 3 buyer markets, $10.3B calculated opportunity. - HS 293499: 3 buyer markets, $8.5B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.